3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
9
Cyclophosphamide
6
fludarabine phosphate
4
aldesleukin
3
Radiotherapy
3
Gemcitabine
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
temsirolimus
2
sargramostim
2
motexafin gadolinium
2
liposomal doxorubicin
2
fludarabine
2
entinostat
2
durvalumab
2
belinostat
2
atezolizumab
2
Sirolimus
2
Paclitaxel
2
Methods
2
Metformin
2
Irinotecan
2
Interferon-alpha
2
Bortezomib
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
valspodar
1
tremelimumab
1
tocilizumab
1
tanespimycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Blood Component Removal
×
Breast
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled